Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy

INTRODUCTION: Liposomal irinotecan (nal-IRI) plus fluorouracil/leucovorin (5-FU/LV) has shown clinical benefit in patients with metastatic pancreatic adenocarcinoma (mPAC) who progressed on gemcitabine-based chemotherapy. However, its role in patients with mPAC previously treated with conventional i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ther Adv Med Oncol
Hauptverfasser: Bang, Kyunghye, Cheon, Jaekyung, Jeong, Jae Ho, Im, Hyeon-Su, Kim, Kyu-pyo, Ryoo, Baek-Yeol, Yoo, Changhoon
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2021
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7983461/
https://ncbi.nlm.nih.gov/pubmed/33796153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211003053
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge